Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.

Murianni V, Signori A, Buti S, Rebuzzi SE, Bimbatti D, De Giorgi U, Chiellino S, Galli L, Zucali PA, Masini C, Naglieri E, Procopio G, Milella M, Fratino L, Baldessari C, Ricotta R, Mollica V, Sorarù M, Tudini M, Prati V, Malgeri A, Atzori F, Di Napoli M, Caffo O, Spada M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Lipari H, Roviello G, Catalano F, Damassi A, Cremante M, Rescigno P, Fornarini G, Banna GL

Open source

DOI: 10.3389/fonc.2024.1307635
Published: 2024
Container: Frontiers in oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2024.1307635,
  title = {Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.},
  author = {Murianni V and Signori A and Buti S and Rebuzzi SE and Bimbatti D and De Giorgi U and Chiellino S and Galli L and Zucali PA and Masini C and Naglieri E and Procopio G and Milella M and Fratino L and Baldessari C and Ricotta R and Mollica V and Sorarù M and Tudini M and Prati V and Malgeri A and Atzori F and Di Napoli M and Caffo O and Spada M and Morelli F and Prati G and Nolè F and Vignani F and Cavo A and Lipari H and Roviello G and Catalano F and Damassi A and Cremante M and Rescigno P and Fornarini G and Banna GL},
  year = {2024},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2024.1307635},
  url = {https://doi.org/10.3389/fonc.2024.1307635}
}

RIS

TY  - JOUR
TI  - Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.
AU  - Murianni V
AU  - Signori A
AU  - Buti S
AU  - Rebuzzi SE
AU  - Bimbatti D
AU  - De Giorgi U
AU  - Chiellino S
AU  - Galli L
AU  - Zucali PA
AU  - Masini C
AU  - Naglieri E
AU  - Procopio G
AU  - Milella M
AU  - Fratino L
AU  - Baldessari C
AU  - Ricotta R
AU  - Mollica V
AU  - Sorarù M
AU  - Tudini M
AU  - Prati V
AU  - Malgeri A
AU  - Atzori F
AU  - Di Napoli M
AU  - Caffo O
AU  - Spada M
AU  - Morelli F
AU  - Prati G
AU  - Nolè F
AU  - Vignani F
AU  - Cavo A
AU  - Lipari H
AU  - Roviello G
AU  - Catalano F
AU  - Damassi A
AU  - Cremante M
AU  - Rescigno P
AU  - Fornarini G
AU  - Banna GL
PY  - 2024
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2024.1307635
UR  - https://doi.org/10.3389/fonc.2024.1307635
ER  -

APA

V, M., A, S., S, B., SE, R., D, B., U, D. G., S, C., L, G., PA, Z., C, M., E, N., G, P., M, M., L, F., C, B., R, R., V, M., M, S., M, T., V, P., A, M., F, A., M, D. N., O, C., M, S., F, M., G, P., F, N., F, V., A, C., H, L., G, R., F, C., A, D., M, C., P, R., G, F., & GL, B. (2024). Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.. Frontiers in oncology. https://doi.org/10.3389/fonc.2024.1307635

Source records

pubmed · retrieved 2026-09-25T01:23:14.694Z